Matches in SemOpenAlex for { <https://semopenalex.org/work/W47291805> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W47291805 endingPage "7" @default.
- W47291805 startingPage "164" @default.
- W47291805 abstract "To present a unilateral central visual field defect in a patient with psoriatic arthritis treated with Methotrexate and folic acid supplement, probably induced by toxic posterior optic neuropathy. The scotoma incompletely resolved after cessation of Methotrexate (MTX) therapy.Serial fundoscopic, perimetric and electrophysiological examination as well as comprehensive neurological investigation including lumbar puncture, carotid sonography, electroneurography, and MRI of the brain.A female patient with psoriatic arthritis on long-standing Methotrexate (MTX 15 mg IM/once a week) therapy suffered first from an acute attack of central visual field defect in her right eye and later on from two subsequent deteriorations of her scotoma within one year. A demyelinating retrobulbar optic neuritis was excluded through repeated comprehensive neurological investigations and unresponsiveness to systemic corticosteroid therapy. A MTX-induced posterior optic neuropathy was suspected and the patient experienced improvement of her visual field defects only six weeks after discontinuing MTX therapy. Further improvement was observed through follow-up perimetric examinations half a year after cessation.Central scotoma with unremarkable optic disc can occur after long-standing treatment with MTX and despite folic acid supplementary therapy. This is most probably due to posterior optic neuropathy. Early cessation of the drug or change to another antimetabolite therapy can stop the deterioration of the visual field changes and even improve them. The exact pathomechanism is still unclear and the involvement of only one eye requires more investigation. MTX-induced posterior optic neuropathy should be included in the differential diagnosis of toxic optic neuropathy. This is getting more frequent than before because of the nowadays standard use of MTX in treatment of many autoimmune collagen diseases." @default.
- W47291805 created "2016-06-24" @default.
- W47291805 creator A5006948914 @default.
- W47291805 creator A5084995630 @default.
- W47291805 creator A5087229690 @default.
- W47291805 creator A5087258218 @default.
- W47291805 date "2006-12-28" @default.
- W47291805 modified "2023-10-18" @default.
- W47291805 title "Visual field changes in methotrexate therapy. Case report and review of the literature." @default.
- W47291805 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17190135" @default.
- W47291805 hasPublicationYear "2006" @default.
- W47291805 type Work @default.
- W47291805 sameAs 47291805 @default.
- W47291805 citedByCount "6" @default.
- W47291805 countsByYear W472918052012 @default.
- W47291805 countsByYear W472918052013 @default.
- W47291805 countsByYear W472918052020 @default.
- W47291805 countsByYear W472918052021 @default.
- W47291805 countsByYear W472918052022 @default.
- W47291805 crossrefType "journal-article" @default.
- W47291805 hasAuthorship W47291805A5006948914 @default.
- W47291805 hasAuthorship W47291805A5084995630 @default.
- W47291805 hasAuthorship W47291805A5087229690 @default.
- W47291805 hasAuthorship W47291805A5087258218 @default.
- W47291805 hasConcept C118487528 @default.
- W47291805 hasConcept C118552586 @default.
- W47291805 hasConcept C141071460 @default.
- W47291805 hasConcept C154945302 @default.
- W47291805 hasConcept C2776058522 @default.
- W47291805 hasConcept C2776572573 @default.
- W47291805 hasConcept C2778233873 @default.
- W47291805 hasConcept C2780640218 @default.
- W47291805 hasConcept C2780837183 @default.
- W47291805 hasConcept C2781059491 @default.
- W47291805 hasConcept C41008148 @default.
- W47291805 hasConcept C64731932 @default.
- W47291805 hasConcept C71924100 @default.
- W47291805 hasConceptScore W47291805C118487528 @default.
- W47291805 hasConceptScore W47291805C118552586 @default.
- W47291805 hasConceptScore W47291805C141071460 @default.
- W47291805 hasConceptScore W47291805C154945302 @default.
- W47291805 hasConceptScore W47291805C2776058522 @default.
- W47291805 hasConceptScore W47291805C2776572573 @default.
- W47291805 hasConceptScore W47291805C2778233873 @default.
- W47291805 hasConceptScore W47291805C2780640218 @default.
- W47291805 hasConceptScore W47291805C2780837183 @default.
- W47291805 hasConceptScore W47291805C2781059491 @default.
- W47291805 hasConceptScore W47291805C41008148 @default.
- W47291805 hasConceptScore W47291805C64731932 @default.
- W47291805 hasConceptScore W47291805C71924100 @default.
- W47291805 hasIssue "3" @default.
- W47291805 hasLocation W472918051 @default.
- W47291805 hasOpenAccess W47291805 @default.
- W47291805 hasPrimaryLocation W472918051 @default.
- W47291805 hasRelatedWork W1434037163 @default.
- W47291805 hasRelatedWork W2002596200 @default.
- W47291805 hasRelatedWork W2006265107 @default.
- W47291805 hasRelatedWork W2015609104 @default.
- W47291805 hasRelatedWork W2027371907 @default.
- W47291805 hasRelatedWork W2042611218 @default.
- W47291805 hasRelatedWork W2091841472 @default.
- W47291805 hasRelatedWork W2138720329 @default.
- W47291805 hasRelatedWork W2758881495 @default.
- W47291805 hasRelatedWork W47291805 @default.
- W47291805 hasVolume "54" @default.
- W47291805 isParatext "false" @default.
- W47291805 isRetracted "false" @default.
- W47291805 magId "47291805" @default.
- W47291805 workType "article" @default.